Friday, September 30, 2022


Biotechnology News Magazine

Rhinomed Confirms Supply Agreement with BTNX

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology has confirmed that it has entered into a supply agreement with BTNX Inc. – one of Canada’s largest manufacturers of rapid antigen test kits.

The supply agreement is for a period of 24 months and covers the supply of Rhinoswab and Rhinoswab Junior for inclusion in BTNX’s range of Covid-19 Rapid Response antigen test kits. This includes supply of Rhinoswab Junior for inclusion in the new Rapid Response COVID-19 Antigen Rapid Test Cassette – Junior Home Test Featuring Rhinoswab Junior – one of the world’s first rapid antigen test kits designed for children.

BTNX is a world leader in rapid, point of care diagnostics across a range of markets. BTNX is the largest supplier of rapid antigen test kits to the Canadian government where it has supplied over 315 million rapid antigen tests to date.

BTNX and Rhinomed can advise that the supply agreement contains standard terms for an agreement of this nature and provides for a minimum binding commitment of 22.5 million swabs over a 24 month period. The agreement is exclusive in the Canadian market and non-exclusive in all other markets. BTNX has informed Rhinomed orders will commence in July 2022.

Pricing remains commercial in confidence however investors should note that the revenue associated with this arrangement has the potential to represent approximately 465% to 475% of reviewed H1FY22 revenues of $3.75m.

Michael Johnson CEO of Rhinomed said, ”The completion of this supply agreement with BTNX is an indicator of the strong market feedback BTNX has received and the impending completion of the Canadian regulatory approval process. The BTNX Rapid Response with Rhinoswab Junior has the potential to transform the way children in Canada are tested. We look forward to a long and successful partnership with BTNX.”

BTNX CEO Iqbal Sunderani said “In the completion of this agreement with Rhinomed, we are pleased to have progressed one step closer to our shared goal of improving the testing experience for children and parents alike. We look forward to our continued collaboration with Rhinomed as we bring this exciting new product to our key markets.”

This report has been authorised for release to the market by the Board. This announcement discloses all material details as required under section 4.1 of ASX Guidance Note 8 in respect of the Supply Agreement.


Capital Raise
In response to increasing demand for Rhinomed’s technology the company has identified the need to expand and scale the company’s manufacturing capacity. The company will undertake a pro rata accelerated nonrenounceable entitlement offer (Entitlement Offer) to raise up to approximately AUD $5.0M to fund working capital required to deliver on strategic objectives.

Under the Entitlement Offer, eligible shareholders are invited to subscribe for one (1) new fully paid ordinary share in Rhinomed (New Share) for every 9.87 existing Rhinomed shares held as at 7pm (AEST) on Monday, 11 April 2022 (Record Date). Bell Potter is the Lead Manager for the Entitlement Offer and will underwrite approximately AUD $3.226M of the accelerated institutional component discussed further below.

All New Shares will be issued at a price of AUD $0.19 per New Share, which represents:

  • a 7.3% discount to the last closing price of $0.205 on 6 April 2022; and
  • a 5.1% discount to the 30 trading day volume weighted average price (VWAP) up to and including 6 April 2022 of AUD $0.205.

Up to 26,323,114 New Shares may be issued under the Entitlement Offer. It is not anticipated that the full amount of New Shares will be issued as only AUD $3.226M of the institutional component of the Entitlement Offer is committed and underwritten.

The Directors of Rhinomed have also confirmed that they will each subscribe for their full entitlements under the Entitlement Offer.

Each New Share issued under the Entitlement Offer will rank equally with each Rhinomed share on issue. Rhinomed will, upon issue of the New Shares under the Offer, seek quotation of the New Shares on the ASX.

Institutional Entitlement Offer

Eligible institutional shareholders will be invited to participate in the accelerated institutional component of the Entitlement Offer (Institutional Entitlement Offer), which is expected to close on 8 April 2022. Approximately $3.228M of the Institutional Entitlement Offer is underwritten by Bell Potter, who will simultaneously undertake a book build with institutional investors, who may be invited to subscribe for any shortfall under the Institutional Entitlement Offer.

Currently, Rhinomed has three substantial shareholders in Mr. W. Whitney George, Prof John McBain (Director) and Mr. Ron Dewhurst (Director), who currently hold approximately 64.54% of the shares on issue in aggregate. Messrs. George, McBain and Dewhurst have elected to take up their full pro-rata entitlements under the Institutional Entitlement Offer, representing approximately $3.228M of the amount to be raised under the Entitlement Offer (being the underwritten component).

Rhinomed has requested a trading halt to complete the Institutional Entitlement Offer.

Retail Entitlement Offer

The retail component of the Entitlement Offer (Retail Entitlement Offer) will be open from 13 April 2022 to eligible retail shareholders in Australia and New Zealand on the Record Date. In addition to each shareholder’s entitlement under the Retail Entitlement Offer, eligible retail shareholders will also be offered the opportunity to subscribe for additional New Shares to the extent there is a shortfall in the Retail Entitlement Offer.

Rhinomed may raise up to approximately AUD $1.651M under the Retail Entitlement Offer if shareholders take up their entitlements in full. Shareholders will also be able to subscribe for additional shares under the Retail Entitlement Offer. The Retail Entitlement Offer will not be underwritten. An offer booklet in respect of the Retail Entitlement Offer is expected to be made available and sent to eligible retail shareholders on 13 April 2022.

The Entitlement Offer is non-renounceable and entitlements will not be tradeable or otherwise transferrable.

Offer Timetable

An indicative timetable of the key dates in respect of the Entitlement Offer is set out below:

41752256 62ef 7756 e659 b3f48aa3b08b
54e1ace0 7a41 1643 874d 4f51720c44c7
Further Information

Further details of the Supply Agreement and the Entitlement Offer are set out in the Investor Presentation also provided to the ASX today. The Investor Presentation contains important information including key risks and foreign selling restrictions with respect to the Entitlement Offer.

If you have any questions, you should seek advice from your stockbroker, accountant or other independent and appropriately licensed professional advisor.

For further information about the Entitlement Offer, you can call the Rhinomed’s shareholder information line on +61 2 9698 5414 at any time between 8.30am and 5.00pm (AEST) on Monday to Friday.

This report has been authorised for release to the market by the Board


At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Neogen Launches New Genomic Management Technology

Neogen notes the Encompass™ platform advances how beef and dairy producers are able to sort and apply genomic data to herd selection and management.


Biotechnology News Magazine
Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.